Today's Share Price Floorsheet Indices/Sub-indices Top Transactions Top Turnovers Top Traded Shares Top Losers Top Gainers Top Brokers IMS Investment Management Services Pvt. Ltd. Dhalko Linkroad -17, Kathmandu sharesansar@gmail.com 977-01-5359786, 5365399 Editor: Usha Sha...
knbwy news analysts supportive of kura/kirin deal despite major selloff (update) sa news thu, nov. 21, 2024 kura stock slides 17% on kyowa kirin deal for ziftomenib sa news wed, nov. 20, 2024 3 comments constellation brands and anheuser-busch pick up market share as overall beer sales...
USDNASDAQ Capital MarketDelayed Price Earnings High Target Price 4.00 Mean Target Price 1.95 Low Target Price 1.14 Standard Deviation: 1.38 Number of Estimates 4 Date of Most Recent Estimate 07/11/23 Created with Highcharts 5.0.7Price Estimate# EstimatesHighMeanLow# Estimates3 Week2 Week1 WeekCur...
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% Yahoo! Finance: News·3mo ago Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias PR Newswire·3mo ago Advertisement. Remove ads. Advertisement...
Once there is a couple of positive net... Captain71 - November 3, 2023 Real stock price share value 0.12 Nibinator - October 28, 2023 Q3 Certainly nice to see quarterly revenue back up above the million mark. Net loss of 197k looks a little worst than it actually is. Strip.....
A high-level overview of iPath® Bloomberg Cocoa Subindex Total Return(SM) ETN (NIB). Stay up to date on the latest price, chart, news, analysis, fundamentals, trading and investment tools.
Related Stocks NASDAQ: GRAL Grail Market Cap $585M Current Price $18.46 NASDAQ: CMPS Compass Pathways Plc Market Cap $239M Current Price $3.56 NASDAQ: KOD Kodiak Sciences Market Cap $377M Current Price $7.27 OTC: CRLBF Cresco Labs
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the ...